Steps to Validate Stathmin-2 as an ALS-Specific Biomarker: Cathleen Lutz, PhD
January 4th 2024The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]